Information Presented at CROI 2021 Related to ViiV Healthcare or its Products

|  |
| --- |
| Summary |
| * The following research related to ViiV Healthcare or its products is to be presented at the 2021 CROI Virtual Meeting from March 6-10, 2021.[1](#_ENREF_1) * Citations are listed alphabetically within their product group. * For ViiV sponsored studies, poster and oral presentation materials are available on the [ViiV Medical Portal](https://www.viivhcmedinfo.com/congress.html). |

Viiv-sponsored research

Dolutegravir-based Regimens

Albano JD, et al. The antiretroviral pregnancy registry: 30 years of monitoring for congenital anomalies. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/9b78f057-922b-49b6-9873-7140af953d16/9b78f057-922b-49b6-9873-7140af953d16_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/f7cbb928-5d2a-49a6-9a2b-37415781601a/f7cbb928-5d2a-49a6-9a2b-37415781601a_viewable_rendition__v.pdf) (REF--ALL-003448; REF--ALL-003449)

Bansi-Matharu L, et al. Association between newer antiretrovirals and increase in body mass index in RESPOND. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/2a81f7e9-d555-493b-a8a4-e86e13f4b906/2a81f7e9-d555-493b-a8a4-e86e13f4b906_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/f3831599-65b8-4f38-b04c-0e82e3310186/f3831599-65b8-4f38-b04c-0e82e3310186_video_rendition__v.mp4) (REF--ALL-003443; REF--ALL-003445)

Benson P, et al. Switching to DTG/3TC FDC is noninferior to TBR for 96 weeks: TANGO subgroup analyses. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/ade937c6-642a-49ae-8c74-da3b948f05cf/ade937c6-642a-49ae-8c74-da3b948f05cf_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/e3349a51-796c-4aa8-bfff-171c324614f9/e3349a51-796c-4aa8-bfff-171c324614f9_video_rendition__v.mp4) (REF--ALL-003439; REF--ALL-003440)

Llibre JM, et al. Inflammatory and atherogenesis markers 148 weeks postswitch to DTG+RPV in sword-1/-2. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/e959b87b-620b-49f5-a933-971cb519722e/e959b87b-620b-49f5-a933-971cb519722e_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/c50c629c-47d7-40b6-8715-4dcdc64689fa/c50c629c-47d7-40b6-8715-4dcdc64689fa_video_rendition__v.mp4) (REF--ALL-003437; REF--ALL-003438)

Neesgaard B, et al. Association between integrase inhibitors (InSTIs) and cardiovascular disease (CVD). Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/5bb01c46-6abd-43cf-81e9-04bcfb6c398d/5bb01c46-6abd-43cf-81e9-04bcfb6c398d_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/e6b9d231-c9b4-46d0-9353-48a8cf08f4f3/e6b9d231-c9b4-46d0-9353-48a8cf08f4f3_video_rendition__v.mp4) (REF--ALL-003446; REF--ALL-003447)

Orkin C, et al. Durable efficay of DTG+3TC in GEMINI-1& 2: Year 3 subgroup analyses. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/9c2d0a8b-dac9-461b-ba2a-9685b15da9bf/9c2d0a8b-dac9-461b-ba2a-9685b15da9bf_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/b6ff670c-7e3b-408c-908e-e69da9e6c6fb/b6ff670c-7e3b-408c-908e-e69da9e6c6fb_video_rendition__v.mp4) (REF--ALL-003441; REF--ALL-003442)

Cabotegravir

Benn P, et al. Long-acting cabotegravir+rilpivirine in older adults: pooled phase 3 week-48 results. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/229513a9-d306-49b2-a153-14a44c90a955/229513a9-d306-49b2-a153-14a44c90a955_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/25e436d3-9466-457e-946b-11b6e4cd20b3/25e436d3-9466-457e-946b-11b6e4cd20b3_video_rendition__v.mp4) (REF--ALL-003452; REF--ALL-003453)

Benn P, et al. Renal/bone outcomes after long-acting cabotegravir + rilpivirine in ATLAS + ATLAS-2M. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/6103db0b-eced-4dce-bb7f-2aa76824d944/6103db0b-eced-4dce-bb7f-2aa76824d944_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/e591aacc-cbfb-4b07-bd12-b92328d9e46d/e591aacc-cbfb-4b07-bd12-b92328d9e46d_video_rendition__v.mp4) (REF--ALL-003454; REF--ALL-003455)

Han K, et al. Cabotegravir PPK simulation to inform Q2M strategies following dosing interruptions. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/76e23e46-c045-4008-aece-96fc84c43afb/76e23e46-c045-4008-aece-96fc84c43afb_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/834b749a-4e05-47e8-b284-81eebc13c5bf/834b749a-4e05-47e8-b284-81eebc13c5bf_viewable_rendition__v.pdf) (REF--ALL-003450; REF--ALL-003451)

Jaeger H, et al. Week 96 efficacy and safety of cabotegravir + rilpivirine every 2 months: ATLAS-2M. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/7f905e36-2088-4251-b151-6b46177204d9/7f905e36-2088-4251-b151-6b46177204d9_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/9ffeed4f-a250-45f4-8caf-4fb9a021d8df/9ffeed4f-a250-45f4-8caf-4fb9a021d8df_video_rendition__v.mp4) (REF--ALL-003456; REF--ALL-003457)

Patel P, et al. Weight and lipid changes in phase 3 cabotegravir and rilpivirine long-acting trials. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/acb3a97c-2b3e-41c6-926d-b8acd1203463/acb3a97c-2b3e-41c6-926d-b8acd1203463_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/ad8c3155-66b8-4508-8acf-beaf37eb2400/ad8c3155-66b8-4508-8acf-beaf37eb2400_video_rendition__v.mp4) (REF--ALL-003458; REF--ALL-003459)

Fostemsavir

Rose B, et al. Reduced susceptibility to temsavir is not linked to IBA or MVC resistance. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/976520ea-701f-4497-b6c1-932ed0f5819a/976520ea-701f-4497-b6c1-932ed0f5819a_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/4bfae3dc-9d0a-4f5e-895e-fc5fa3d07700/4bfae3dc-9d0a-4f5e-895e-fc5fa3d07700_video_rendition__v.mp4) (REF--ALL-003462; REF--ALL-003463)

Maturation Inhibitor (MI) - GSK3640254

Jeffrey JL, et al. GSK3640254 is a novel maturation inhibitor with an optimized virology profile. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/09382592-d915-409e-8559-d6f48d961179/09382592-d915-409e-8559-d6f48d961179_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/939178d4-52f0-4fc2-b358-240abd622f3c/939178d4-52f0-4fc2-b358-240abd622f3c_video_rendition__v.mp4) (REF--ALL-003466; REF--ALL-003468)

Spinner C, et al. Phase IIa proof-of-concept trial of next-generation maturation inhibitor GSK3640254. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Oral Presentation. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/70211a07-6956-43e2-8e1d-32313661cdc1/70211a07-6956-43e2-8e1d-32313661cdc1_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/fcf9242f-9e4e-4fc8-a22d-946a0f1a8366/fcf9242f-9e4e-4fc8-a22d-946a0f1a8366_video_rendition__v.mp4) (REF--ALL-003464; REF--ALL-003465)

Other Disease-Related Content

Berko J, et al. RCT of an online mental health intervention among older PLWH during COVID-19 pandemic. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Oral Presentation. [(slides only)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/2a01e150-5c03-41aa-a990-b713a852b27c/2a01e150-5c03-41aa-a990-b713a852b27c_viewable_rendition__v.pdf) [(slides + author audio)](https://d201nm4szfwn7c.cloudfront.net/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/02212f6d-503a-43ea-8f60-7bc7c6a57738/02212f6d-503a-43ea-8f60-7bc7c6a57738_video_rendition__v.mp4) (REF--ALL-003469; REF--ALL-003470)

**Some information contained in this response may not be included in the approved Prescribing Information. This response is not intended to offer recommendations for administering this product in a manner inconsistent with its approved labeling.**

**In order for ViiV Healthcare to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 877–844–8872. Please consult the attached Prescribing Information.**

**This response was developed according to the principles of evidence-based medicine and, therefore, references may not be all-inclusive.**

References

1. Program and Conference Information. CROI 2021, Virtual Event. March 6-10, 2021. Available at: <https://www.croiconference.org/>. Accessed March 2, 2021.